Background: Insufficient response to monotreatment for depression is a common phenomenon in clinical practice. Even so, evidence indicating how to proceed in such cases is sparse. Methods: This study looks at the second phase of a sequential treatment algorithm, in which 103 outpatients with moderately severe depression were initially randomized to either short-term supportive psychodynamic therapy (PDT) or antidepressants. Patients who reported less than 30% symptom improvement after 8 weeks were offered combined treatment. Outcome measures were the Hamilton Depression Rating Scale (HAM-D), the Clinical Global Impression of Severity and Improvement, the SCL-90 depression subscale and the EuroQOL questionnaire. Results: Despite being nonresponsive, about 40% of patients preferred to continue with monotherapy. At treatment termination, patients initially randomized to PDT had improved more than those initially receiving antidepressants, as indicated by the HAM-D and the EuroQOL, independently of whether the addition was accepted or not. Conclusions: Starting with psychotherapy may be preferable in mildly and moderately depressed outpatients. For patients who receive either PDT or antidepressants, combined therapy after early nonresponse seems to be helpful. Nevertheless, this sequential strategy is not always preferred by patients.

1.
Casacalenda N, Perry JC, Looper K: Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy and control conditions. Am J Psychiatry 2002;159:1354–1360.
2.
Cuijpers P, van Straten A, Andersson G, van Oppen P: Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008;76:909–922.
3.
Cuijpers P, van Straten A, van Oppen P, Andersson G: Are psychological and pharmacological interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 2008;69:1675–1685.
4.
Hollon SD, Jarrett RB, Nierenberg AA, Thase ME, Trivedi M, Rush AJ: Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? J Clin Psychol 2005;66:455–468.
5.
de Maat SM, Dekker J, Schoevers RA, de Jonghe F: Relative efficacy of psychotherapy and combined therapy in the treatment of depression: a meta-analysis. Eur Psychiatry 2007;22:1–8.
6.
Cuijpers P, Dekker J, Hollon SD, Andersson G: Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry 2009;70:1219–1229.
7.
de Jonghe F, Kool S, van Aalst G, Dekker J, Peen J: Combining psychotherapy and antidepressants in the treatment of depression. J Affect Disord 2001;64:217–229.
8.
Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462–1470.
9.
de Jonghe F, Hendriksen M, van Aalst G, Kool S, Peen J: Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. Br J Psychiatry 2004;185:37–45.
10.
de Maat S, Dekker J, Schoevers R, de Jonghe F: Relative efficacy of psychotherapy and combined therapy in the treatment of depression: a meta-analysis. Eur Psychiatry 2007;22:108.
11.
de Maat S, Dekker J, Schoevers R, van Aalst G, Gijsbers-van Wijk C, Hendriksen M, Kool S, Peen J, Van R, de Jonghe F: Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. Depress Anxiety 2008;25:565–574.
12.
Blom MBJ: Combination Treatment for Depressed Outpatients: Efficacy and Prediction of Outcome. Amsterdam, Free University of Amsterdam, 2008.
13.
Segal Z, Vincent P, Levitt A: Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy improving outcomes in depression. J Psychiatry Neurosci 2002;18:1–19.
14.
Fava M, Ruini C, Rafanelli C: Sequential treatment of mood and anxiety disorders. J Clin Psychiatry 2005;66:1392–1400.
15.
Fava A, Tomba E: New modalities of assessment and treatment planning in depression. The sequential approach. CNS Drugs 2010;24:453–465.
16.
Frank E, Grochocinski VJ, Spanier CA, Buysse DJ, Cherry CR, Houck PR: Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. J Clin Psychiatry 2000;61:51–57.
17.
Fava GA, Grandi S, Zielezny M, Canestrari R, Morphy MA: Cognitive behavioral treatment of residual symptoms in primary major depressive disorders. Am J Psychiatry 1994;151:1295–1299.
18.
Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R: Four year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996;153:1443–1445.
19.
Fava GA, Rafanelli C Grandi S, Canestrari R, Morphy MA: Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998;155:1443–1445.
20.
Paykel ES, Scott J, Cornwal PL, Abbot R, Crane C, Pope M, Johnson AL: Duration of relapse prevention after cognitive therapy in residual depression: follow-up controlled trial. Br J Psychiatry 2005;35:59–68.
21.
Teasdale JD, Segal ZV, Williams JMG, Ridgeway VA, Soulsby JM, Lou MA: Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000;68:615–623.
22.
Perlis RH, Nierenberg AA, Alpert JE, Pava J, Matthews JD, Buchin J, Sickinger AH, Fava M: Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol 2002;22:474–480.
23.
Petersen T, Harly R, Papakostas G, Montoya HD, Fava M, Alpert JE: Continuation cognitive behavioral therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. Psychol Med 2004;34:555–561.
24.
Ma SH, Teasdale JD: Mindfulness-based cognitive therapy. J Consult Clin Psychol 2004;72:31–40.
25.
Bockting CLH, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, Kamphuis JH: Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol 2005;73:647–657.
26.
Kuyken W, Byford S, Taylor RS, Watkins E, Hoden E, White K, Barrett B, Byng R, Evans A, Mullan E, Teasdale JD: Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008;76:966–978.
27.
Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava W, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007;164:739–752.
28.
Leichsenring F, Rabung S, Leibing E: The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 2004;61:1208–1216.
29.
Driessen E, Cuijpers P, de Maat SCM, Abbass A, de Jonghe F, Dekker JM: The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis. Clin Psychol Rev 2010;30:25–36.
30.
Abbass A, Driessen, E: The efficacy of short-term psychodynamic psychotherapy for depression: a summary of recent findings (letter to the editor). Acta Psychiatr Scand 2010;121:398–399.
31.
Blagys M, Hilsenroth M: Distinctive features of short-term psychodynamic-interpersonal psychotherapy: an empirical review of the comparative psychotherapy process literature. Clin Psychol Sci Pract 2000;7:167–188.
32.
Leichsenring F: Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioral therapy in depression: a meta-analytic approach. Clin Psychol Rev 2001;21:401–419.
33.
Maina G, Rosso G, Crespi C, Bogetto F: Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: a pilot study. Psychother Psychosom 2007;76:298–305.
34.
Maina G, Rosso G, Bogetto F: Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results. J Affect Disord 2009;114:200–207.
35.
Salminen J, Karisson H, Hietala J, Kajander J, Aalto S, Markkula J, Rasi-Hakala H, Toikka T: Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. Psychother Psychosom 2008;77:351–357.
36.
Dekker JJM, Koelen JA, Van H, Schoevers RA, Peen J, Hendriksen M, Kool S, van Aalst G, de Jonghe F: Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment. J Affect Disord 2008;109:183–188.
37.
Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–296.
38.
Van HL, Dekker J, Koelen JA, Kool S, van Aalst G, Hendriksen M, Peen J, Schoevers RA: Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression. Psychother Res 2009;19:205–212.
39.
Fava M, Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179–200.
40.
Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649–659.
41.
Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF: Major depressive subtypes and treatment response. Biol Psychiatry 1997;42:568–576.
42.
Van Henricus L, Dekker J, Peen J, van Aalst G, Schoevers RA: Identifying patients at risk for complete nonresponse in the outpatients treatment of depression. Psychother Psychosom 2008;77:358–364.
43.
Dekker J, Molenaar PJ, Kool S, van Aalst G, Peen J, de Jonghe F: Dose effect relations in time-limited combined psycho-pharmacological treatment for depression. Psychol Med 2005;35:47–58.
44.
Hendriksen M, Van HL, Schoevers RA, de Jonghe F, Gijsbers-van Wijk CM, Peen J, Dekker JJ: Therapist judgment of defense styles and therapeutic technique related to outcome in psychodynamic psychotherapy of depression. Psychother Psychosom 2011;80:377–379.
45.
Kool S, Dekker J, Duijsens IJ, de Jonghe F, Puite B: Changes in personality pathology after pharmacotherapy and combined therapy for depressed patients. J Pers Disord 2003;17:60–72.
46.
Kool S, Dekker J, Duijsens IJ, de Jonghe F, Puite B: Efficacy of combined therapy and pharmacotherapy with depressed patients with or without personality disorders. Harv Rev Psychiatry 2003;11:133–141.
47.
Dekker J, Koelen JA, Van HL, Schoevers RA, Peen J, Hendriksen, M, Kool S, van Aalst G, de Jonghe F: Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression. J Affect Disord 2008;109:183–188.
48.
de Jonghe F, Hendriksen M, van Aalst G, Kool S, Peen J, Van R, van den Eijnden E, Dekker J: Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. Br J Psychiatry 2004;185:37–45.
49.
de Maat S, Dekker J, Schoevers R, van Aalst G, de Jonghe F, Gijsbers-van Wijk C, Hendriksen M, Kool S, Peen J, Van R: Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. Depress Anxiety 2008;25:565–574.
50.
Molenaar, P, Dekker J, Schouws S, Peen J, Schoevers R: Recovery of social functioning during the treatment of depression. Depress Anxiety 2006;23:1–10.
51.
Van HL, Schoevers RA, Kool S, Hendriksen M, Peen J, Dekker J: Does early response predict outcome in psychotherapy and combined therapy for major depression? J Affect Disord 2008;105:261–265.
52.
Van HL, Dekker J, Koelen J, Kool S, van Aalst G, Hendriksen M, Peen J, Schoevers R: Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression. Psychother Res 2009;19:205–212.
53.
de Jonghe F, Rijnierse P, Janssen R: Psychoanalytic supportive psychotherapy. J Am Med Assoc 1994;42:421–446.
54.
de Jonghe F: Kort en Krachtig (Brief and Potent). Short Psychodynamic Supportive Psychotherapy. Amsterdam, Benecke, 2005.
55.
de Jonghe F, Dekker J, Kwakman H, Huyser J: Sensitivity of the depression and anxiety list (DAL) to early response in patients with major depression treated with antidepressants. Int J Methods Psychiatr Res 1996;5:1–5.
56.
Huyser J, de Jonghe F, Jonkers F, Schalken HFA: The Manual for the Diagnosis of Major Depression (MDMD): description and reliability. Int J Methods Psychiatr Res 1996;6:1–4.
57.
Guy W: ECDEU Assessment Manual for Psychopharmacology (revised). US Department of Health, Education and Welfare Pub. Rockville, National Institute of Mental Health, DHEW Publ No ADM 76-338, 1976.
58.
Arrindell WA, Ettema JMM: SCL-90. Handleiding bij een multidimensionele psychopathologie-indicator. Lisse, Swets and Zeitlinger, 1986.
59.
Tuynman-Qua H, de Jonghe F: Quality of Life Depressie Schaal. Houten, Ibero, 1992.
60.
Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G, Friedman ES, Biggs MM, Sackeim HA, Shores-Wilson K, McGrath PJ, Lavori PW, Miyahar AS, Rush AJ: Acceptability of second-step treatment of depressed outpatients: a STAR*D report. Am J Psychiatry 2007;164:753–760.
61.
Pigott HE, Leventhal AM, Alter GS, Boren JJ: Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 2010;79:267–279.
62.
Hoyer J, Höfler M: Do pharmacotherapy and/or psychotherapy work in depression? It depends! Psychother Psychosom 2011;80:245.
63.
Huf W, Kalcher K, Kasper S: Widespread methodological problems limit validity of meta-analytic results. Psychother Psychosom 2011;80:246.
64.
Pigott HE, Alter GS: In response to ‘Do pharmacotherapy and/or psychotherapy work in depression? It depends!’ and ‘Widespread methodological problems limit validity of meta-analytic results’. Psychother Psychosom 2011;80:247–248.
65.
Linham R, Scott J: Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002;105:164–172.
66.
Demyttenaere K: Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol 2003;13(suppl 3):S69–S75.
67.
Simons AD, Levine JL, Lustman PJ, Murphy GE: Patient attrition in a comparative outcome study of depression: a follow-up report. J Affect Disord 1984;6:163–173.
68.
Reynolds CF, Frank E, Perel JM, Imber SD, Cornes C, Morycz RK, Mazumdar S, Miller MD, Pollock BG, Rifai AH: Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry 1992;49:1687–1692.
69.
Christensen H, Griffiths KM, Mackinnon AJ, Brittliffe K: Online randomized controlled trial of brief and full cognitive behaviour therapy for depression. Psychol Med 2006;36:1737–1746.
70.
Cahill J, Barkham M, Hardy G, Rees A, Shapiro DA, Stiles WB, Macaskill N: Outcomes of patients completing and not completing cognitive therapy for depression. Br J Clin Psychol 2003;42:133–143.
71.
Blom MB, Spinhoven P, Hoffman T, Jonker K, Hoencamp E, Haffmans PM, van Dyck R: Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. J Affect Disord 2007;104:119–126.
72.
Warden D, Trevedi MH, Wisniewski R, Lesser IM, Mitchell J, Balasubramani GK, Fava M, Shores-Wilson K, Stegman D, Rush AJ: Identifying risk for attrition during treatment for depression. Psychother Psychosom 2009;78:372–379.
73.
Cheng M: New approaches for creating the therapeutic alliance: solution-focused interviewing, motivational interviewing, and the medication interest model. Psychiatr Clin North Am 2007;30:157–166.
74.
Ruhé HG, Dekker JJ, Peen J, Holman R, de Jonghe F: Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry 2005;46:417–427.
75.
Mergl R, Henkel V, Allgaier A, Kramer D, Hautzinger M, Kohnen R, Coyne J, Heger U: Are treatment preferences relevant in response to serotonergic antidepressants and cognitive-behavioral therapy in depressed primary care patients? Results from a randomized controlled trial including a patients’ choice arm. Psychother Psychosom 2011;80:39–47.
76.
Lacoviello BM, Alloy LB, Abramson LY, Whitehouse WG, Hogan ME: The role of cluster B and C personality disturbance in the course of depression: a prospective study. J Pers Disord 2007;21:371–383.
77.
Lichtenberg P, Belmaker R: Subtyping major depressive disorder. Psychother Psychosom 2010;79:131–135.
78.
Smits JAJ, Minhajuddin A, Thase ME, Jarrett RB: Outcomes of acute phase cognitive therapy in outpatients with anxious versus nonanxious depression. Psychother Psychosom 2012;81:153–160.
79.
Tomba E: Nowhere patients. Psychother Psychosom 2012;81:69–72.
80.
Bech P: Struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychother Psychosom 2010;79:331–338.
81.
Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina, Flynn M, Harper L, Levy M, Rickels K, Pollack M: A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A study). Psychother Psychosom 2012;81:87–97.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.